A new study from the University of California, Santa Cruz, published October 15 in Nature Neuroscience, demonstrates how psilocybin - the psychoactive compound in "magic mushrooms" - remodels neural circuits in the brain. The research reveals that this compound can trigger beneficial structural changes without producing hallucinations, a finding that could reshape how scientists develop treatments for psychiatric conditions.
The researchers tracked individual dendritic spines over several weeks in mice. They observed that psilocybin rapidly increased new spine formation within 24 hours. These new connections also matured faster than normal, developing into large "mushroom" shapes equipped with abundant neurotransmitter receptors, rather than remaining as small, unstable structures.
How stress changes psilocybin's effects
The researchers discovered that psilocybin's impact depends on the brain's condition. In healthy mice, the drug caused a temporary spike in new connections that gradually returned to baseline over three weeks, while older connections were eliminated. This maintained structural stability while updating circuits.
However, in chronically stressed mice - a model that mimics human depression, the drug sparked a much stronger surge in new spine formation while simultaneously preventing the excessive loss of existing connections. This suggests psilocybin may specifically help restore circuits disrupted by stress, offering a new perspective on its therapeutic potential for depression and PTSD.
Perhaps most significantly, the study decoupled structural plasticity from hallucinogenic effects. The team focused on serotonin 2A receptors - proteins on cell membranes that psilocybin binds to. When these receptors were restored only in Layer 5 pyramidal neurons (principal output cells in the brain's outer layer), psilocybin triggered new synapse formation and maturation, but the mice showed no head-twitch response - the standard indicator of hallucinogenic activity in rodents. Conversely, removing these receptors from the same neurons blocked structural changes while leaving the hallucinogenic response intact.
This finding matters because it demonstrates that the cellular mechanisms driving therapeutic circuit remodeling operate through pathways distinct from those causing perceptual alterations. As the researchers noted, this provides a "promising blueprint for designing non-hallucinogenic drug analogs" that could deliver rapid, lasting antidepressant benefits without psychedelic side effects - making such treatments safer and accessible to more patients.
The FDA recently held a public hearing on integrating psychedelic-assisted therapies into healthcare, reflecting growing regulatory momentum.